UNITED THERAPEUTICS CORP Form 8-K August 11, 2005

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2005

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware 000-26301 52-1984749
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

Silver Spring, MD
(Address of Principal Executive Offices)

(Zip Code)

Registrant s telephone number, including area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On August 10, 2005, the Company issued a press release announcing the results of the European Union Mutual Recognition Procedure with respect to marketing authorization approvals for Remodulin®. A copy of this press release is attached hereto as Exhibit 99.1.

Item 9.01. Exhibits

(c) Exhibits

Exhibit No. - Description of Exhibit

99.1 Press release dated August 10, 2005

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: August 10, 2005 By: /s/ Paul A. Mahon

Name: Paul A. Mahon Title: General Counsel

3

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Press release dated August 10, 2005

4